EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version).

CHAIRPERSONS & INVITED SPEAKERS: Alfredo Alberti, Italy; Miriam Alter, USA; Yves Benhamou, France; Paolo Bonanni, Italy; Feruccio Bonino, Italy; Flavia Bortolotti, Italy; Jordi Bruix, Spain; Maurizia Brunetto, Italy; Massimo Colombo, Italy; Graham Cooksley, Australia; Antonia Craxi, Italy; Valeer Desmet, Belgium; Philippe Duclos, Switzerland; Geoffrey Dusheiko, UK; Rafael Esteban, Spain; Patrizia Farci, Italy; Giovanna Fattovich, Italy; Carlo Ferrari, Italy; Stephanos Hadziyannis, Greece; Jenny Heathcote, Canada; Jay Hoofnagle, USA; Yun-Fan Liaw, Taiwan; Stephen Locarnini, Australia; Michael Manns, Germany; Patrick Marcellin, France; Pem Namgyal, Switzerland; Nikolai Naoumov, UK; Jean-Michel Pawlotsky, France; Robert Perrillo, USA; Stanislas Pol, France; Patrizia Pontisso, Italy; Giovanni Raimondo, Italy; Mario Rizzetto, Italy; Michael Roggendorf, Germany; Didier Samuel, France; Solko Schalm, The Netherlands; Daniel Shouval, Israel; Howard Thomas, UK; Christian Trépo, France; Pierre Van Damme, Belgium; Hans Will, Germany; Theresa Wright, USA; Stephan Zeuzem, Germany; Fabien Zoulim, France

[1]  A. Shakil,et al.  Fulminant hepatic failure , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[2]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[3]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[4]  P. Tebas,et al.  Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. , 2002, The Journal of infectious diseases.

[5]  A. Lok,et al.  HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. , 2002, Hepatology.

[6]  D. Fong,et al.  Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation , 2002, Hepatology.

[7]  R. Fontana,et al.  Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. , 2002, Gastroenterology.

[8]  D. Goldmann.  Blood-borne pathogens and nosocomial infections. , 2002, The Journal of allergy and clinical immunology.

[9]  A. Zanella,et al.  Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels , 2002, Annals of Internal Medicine.

[10]  E. Schiff,et al.  Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B , 2002, Hepatology.

[11]  S. Hadziyannis,et al.  Course of virologic breakthroughs under long‐term lamivudine in HBeAg‐negative precore mutant HBV liver disease , 2002, Hepatology.

[12]  A. Andriulli,et al.  Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. , 2002, Journal of hepatology.

[13]  T. Berg,et al.  Increasing applicability of liver transplantation for patients with hepatitis B–related liver disease , 2002, Hepatology.

[14]  H. Chiou,et al.  Long‐term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B , 2002, Hepatology.

[15]  M. Jonas,et al.  Clinical trial of lamivudine in children with chronic hepatitis B. , 2002, The New England journal of medicine.

[16]  A. Lok,et al.  Clinical significance of hepatitis B virus genotypes , 2002, Hepatology.

[17]  F. Chan,et al.  Survival and Prognostic Indicators in Patients with Hepatitis B Virus–Related Cirrhosis After Onset of Hepatic Decompensation , 2002, Journal of clinical gastroenterology.

[18]  Jean-Michel Pawlotsky,et al.  Molecular diagnosis of viral hepatitis. , 2002, Gastroenterology.

[19]  V. Wong,et al.  Is it safe to stop lamivudine after the emergence of YMDD mutants during lamivudine therapy for chronic hepatitis B , 2002 .

[20]  H. Margolis,et al.  Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. , 2002, The Journal of infectious diseases.

[21]  H. Margolis,et al.  Strengthening immunization systems and introduction of hepatitis B vaccine in central and eastern Europe and the newly independent states. , 2002, Vaccine.

[22]  M. Brunetto,et al.  Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. , 2002, Journal of hepatology.

[23]  P. Beutels.  Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). , 2001, Health economics.

[24]  J. Sung,et al.  The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta‐analysis , 2001, Alimentary pharmacology & therapeutics.

[25]  D. Pillay,et al.  Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir , 2001, Gut.

[26]  B. McMahon,et al.  Serologic and Clinical Outcomes of 1536 Alaska Natives Chronically Infected with Hepatitis B Virus , 2001, Annals of Internal Medicine.

[27]  G. Ippolito,et al.  Risk of HIV and Other Blood‐Borne Infections in the Cardiac Setting , 2001, Annals of the New York Academy of Sciences.

[28]  F. Kinjo,et al.  Hepatitis B virus concentrations in serum determined by sensitive quantitative assays in patients with established chronic hepatitis delta virus infection , 2001, Journal of medical virology.

[29]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[30]  D. Vassilopoulos,et al.  Hepatitis B e antigen–negative chronic hepatitis B , 2001, Hepatology.

[31]  D. Thabut,et al.  Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: Results of a pilot study , 2001, Hepatology.

[32]  S. Bloor,et al.  Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus , 2001, Gut.

[33]  C. Bréchot,et al.  Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely “occult”? , 2001, Hepatology.

[34]  N. Leung,et al.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy , 2001, Hepatology.

[35]  A. Lok,et al.  Management of hepatitis B: 2000--summary of a workshop. , 2001, Gastroenterology.

[36]  G. Leroux-Roels,et al.  Vaccine- and Hepatitis B Immune Globulin-Induced Escape Mutations of Hepatitis B Virus Surface Antigen , 2001, Journal of Biomedical Science.

[37]  D. Suh,et al.  Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B , 2001 .

[38]  S. Paik,et al.  Economic evaluation of the societal costs of hepatitis B in South Korea , 2001, Journal of gastroenterology and hepatology.

[39]  R. Perrillo.  Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. , 2001, Gastroenterology.

[40]  E. Sagnelli,et al.  Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis , 2000, Hepatology.

[41]  A. Lok,et al.  Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e Antigen–negative patients receiving lamivudine therapy , 2000, Hepatology.

[42]  H. Lee,et al.  Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea , 2000, Hepatology.

[43]  J. Hoofnagle,et al.  Long‐term therapy of chronic hepatitis B with lamivudine , 2000, Hepatology.

[44]  E. Schiff,et al.  Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants , 2000, Hepatology.

[45]  F. Donato,et al.  Mortality for liver disease in patients with HIV infection: a cohort study. , 2000, Journal of acquired immune deficiency syndromes.

[46]  Y. Liaw,et al.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.

[47]  A. Buckley,et al.  Practice Guidelines for Liver Biopsy , 2000 .

[48]  K. Shiraki.  Perinatal transmission of hepatitis B virus and its prevention , 2000, Journal of gastroenterology and hepatology.

[49]  Mei‐Hwei Chang.  Natural history of hepatitis B virus infection in children , 2000, Journal of gastroenterology and hepatology.

[50]  A. Dhillon,et al.  Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial , 2000, Gut.

[51]  Ding‐Shinn Chen,et al.  Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. , 2000, Gastroenterology.

[52]  S. Harbarth,et al.  The economic burden of Hepatitis B in Germany , 2000, European Journal of Epidemiology.

[53]  H. Margolis,et al.  Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. , 2000, The Journal of infectious diseases.

[54]  A. Grant,et al.  Guidelines on the use of liver biopsy in clinical practice , 1999, Gut.

[55]  F. Zipp,et al.  No increase in demyelinating diseases after hepatitis B vaccination , 1999, Nature Medicine.

[56]  D. Cooper,et al.  Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. , 1999, The Journal of infectious diseases.

[57]  Y. Liaw,et al.  Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B , 1999, Hepatology.

[58]  W. Gerlich,et al.  Hepatitis viruses and the safety of blood donations , 1999, Journal of viral hepatitis.

[59]  A. Andriulli,et al.  Changing pattern of chronic hepatitis D in Southern Europe. , 1999, Gastroenterology.

[60]  E. Schiff,et al.  Multicenter study of lamivudine therapy for hepatitis B after liver transplantation , 1999, Hepatology.

[61]  M. Loriot,et al.  Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men , 1999, Hepatology.

[62]  C. Chu,et al.  Long‐term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection , 1999, Hepatology.

[63]  A. Feld,et al.  Health care costs associated with chronic hepatitis B. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[64]  P Coriat,et al.  Impact of hepatitis B and C virus on kidney transplantation outcome , 1999, Hepatology.

[65]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[66]  F. Chang,et al.  Sero‐clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis , 1998, Hepatology.

[67]  R. Scheig.  Acute and chronic viral hepatitis. , 1998, Lippincott's primary care practice.

[68]  K. Chayama,et al.  Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. , 1998, Journal of hepatology.

[69]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .

[70]  J. Delattre,et al.  Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C , 1998, Hepatology.

[71]  P. Vajro,et al.  Interferon: a meta-analysis of published studies in pediatric chronic hepatitis B. , 1998, Acta gastro-enterologica Belgica.

[72]  J. Hoofnagle,et al.  Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. , 1997, Gastroenterology.

[73]  M. Lai,et al.  Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. , 1997, The New England journal of medicine.

[74]  C. J. Chen,et al.  Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. , 1997, American journal of epidemiology.

[75]  R. Tubiana,et al.  Effects of Lamivudine on Replication of Hepatitis B Virus in HIV-Infected Men , 1996, Annals of Internal Medicine.

[76]  H. Hsu,et al.  Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. , 1996, JAMA.

[77]  D. Häussinger,et al.  Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. , 1996, The New England journal of medicine.

[78]  E. Schiff,et al.  Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. , 1995, Gastroenterology.

[79]  A. Lok,et al.  Pathogenic role of hepatitis B virus in hepatitis B surface antigen—negative decompensated cirrhosis , 1995, Hepatology.

[80]  E. Christensen,et al.  Occurrence of hepatocellular carcinoma and decompensation in western european patients with cirrhosis type B , 1995, Hepatology.

[81]  P. van Eyken,et al.  Treatment of chronic hepatitis D with interferon alfa-2a. , 1994, The New England journal of medicine.

[82]  G. Alexander,et al.  Liver transplantation in European patients with the hepatitis B surface antigen. , 1993, The New England journal of medicine.

[83]  A. Lok,et al.  Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. , 1993, Gastroenterology.

[84]  A. Detsky,et al.  Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.

[85]  G. Meucci,et al.  The Natural History of Asymptomatic Hepatitis B Surface Antigen Carriers , 1993, Annals of Internal Medicine.

[86]  I. Lauder,et al.  A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. , 1992, Gastroenterology.

[87]  B. McMahon,et al.  Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. , 1992, The American journal of medicine.

[88]  C. Chu,et al.  Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study , 1991, Hepatology.

[89]  G. Fattovich,et al.  Natural history and prognostic factors for chronic hepatitis type B. , 1991, Gut.

[90]  C. Lai,et al.  Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children. , 1991, The Quarterly journal of medicine.

[91]  H. Margolis,et al.  The emergence of hepatitis B as a sexually transmitted disease. , 1990, The Medical clinics of North America.

[92]  B. McMahon,et al.  Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. , 1990, Archives of internal medicine.

[93]  H. Margolis,et al.  The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. , 1990, JAMA.

[94]  M. Brunetto,et al.  Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen , 1989, Hepatology.

[95]  G. Minuk,et al.  Passive and active immunization against hepatitis B virus infection: optimal scheduling in healthy young adults. , 1989, Clinical and investigative medicine. Medecine clinique et experimentale.

[96]  G Realdi,et al.  Long‐term follow‐up of anti‐HBe‐positive chronic active hepatitis B , 1988, Hepatology.

[97]  Y. Ghendon.  Perinatal transmission of hepatitis B virus in high-incidence countries. , 1987, Journal of virological methods.

[98]  A. Lok,et al.  Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. , 1987, Gastroenterology.

[99]  R. Purcell,et al.  Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. , 1987, Gastroenterology.

[100]  M. Buti,et al.  Immunoprophylaxis of perinatal transmission of the hepatitis B virus: Efficacy of hepatitis B immune globulin and hepatitis B vaccine in a low‐prevalence area , 1986, Journal of medical virology.

[101]  P. Coursaget,et al.  Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. , 1985, The Journal of infectious diseases.

[102]  T R Bender,et al.  Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. , 1985, The Journal of infectious diseases.

[103]  M. Manns,et al.  Hepatitis B infection in heart transplant patients. , 2001, Gastroenterology.

[104]  W. Maddrey.  Hepatitis B: an important public health issue. , 2000, Journal of medical virology.

[105]  H. Rosen,et al.  Hepatitis B and C in the liver transplant recipient. , 2000, Seminars in liver disease.

[106]  D. Brown,et al.  Diagnosis of acute and chronic hepatitis C , 2000 .

[107]  G. Lau,et al.  Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  L. Simonsen,et al.  Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. , 1999, Bulletin of the World Health Organization.

[109]  E. Schiff,et al.  A Placebo Controlled Study of Lamivudine and Interferonalpha-2b in Patients with Chronic Hepatitis B Who PreviouslyFailed Interferon Therapy , 1998 .

[110]  M. Kane.  Global programme for control of hepatitis B infection. , 1995, Vaccine.

[111]  M. Rizzetto,et al.  Advances in hepatitis D virus biology and disease. , 1994, Progress in liver diseases.

[112]  E. Christensen,et al.  Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). , 1994, Journal of hepatology.

[113]  A. Liberati,et al.  Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature. , 1993, Journal of hepatology.

[114]  W P Havens,et al.  Viral hepatitis. , 1970, The Medical clinics of North America.